To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Blood and cerebrospinal f… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease

Chapter in book
Authors S Lista
Henrik Zetterberg
S. O’Bryant
Kaj Blennow
H. Hampel
Published in Dementia, Edited ByDavid Ames, John T. O'Brien, Alistair Burns
Pages 528-538
ISBN 9781498703116
Publisher CRC Press
Place of publication Boca Raton
Publication year 2017
Published at Institute of Biomedicine
Pages 528-538
Language en
Links dx.doi.org/10.1201/9781315381572
Subject categories Other Medical Sciences

Abstract

In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80% (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?